Categories
Connect with us on LinkedIn
On-site ePRO in Action: A Recap of Castor’s Product Spotlight
Castor’s on-site ePRO adds in-clinic PRO capture to the ePRO/CDMS workflow you already use. Staff use a site...
EQ-5D in European Trials: When Generic QoL Measures Actually Matter
Analysis of 735 FDA drug approvals reveals 0% EQ-5D labeling inclusion, while European HTA bodies demonstrate 18% technology...
ePRO, eCOA 101: Everything You Need to Know About ePRO and eCOA
Electronic Clinical Outcome Assessment (ECOA) and electronic Patient Reported Outcomes (ePRO) represent far more than digital surveys in...
Why eCOA Still Fails in Clinical Trials: Practical Strategies to Fix Baseline Data Problems
Electronic clinical outcome assessments (eCOA) were supposed to solve data quality and amplify the patient voice. Yet missing...
How a 3-Person Team Got to Phase 3 — Without the Overhead
Gameto proves you don’t need a large CRO or a floor of data managers to run complex global...
From Hype to Health: What Sword Health Got Right About Evidence
Sword Health didn’t follow the typical digital health playbook. Instead of rushing to market, they invested early in...
The New Standard in Participant-Centric Trials: What Castor’s 2025 Updates Reveal About the Future of Clinical Research
Explore how Castor’s 2025 updates reduce site burden and boost compliance through scalable, flexible DTP workflows.
Building Biotech: From Science to Scale – Strategic Lessons from the Frontline
Hard truths on scaling biotech: data isn’t enough, CEOs matter, and funding follows story—not science.
Do Patients Really Understand Clinical Trials?
Poor comprehension of informed consent disrupts trials. Here’s how to fix it—with data, tech, and actual patient understanding.
Building a Safer, Smarter Future: A Tiered Approach to AI in Life Sciences
Adopt AI in clinical research with confidence using a risk-based framework that ensures privacy, security, and regulatory alignment.
Why a Life Sciences Museum Matters—And What It Can Teach Us About the Future of Medicine
What a Museum of Medicine can teach us about trials, trust, and how the public sees (or doesn’t...
The Catch-22 of eConsent: The Missed Opportunity for Improved Clinical Trials
It’s time to move beyond digital PDFs. Discover how real eConsent can transform trials, reduce dropout, and respect...
Build vs. Buy vs. Partner in Life Sciences: Making the Right Call
How do you decide between building, buying, or partnering? Learn key decision factors and red flags to avoid...
Do CROs Need to Reinvent Themselves in 2025? A Deep Dive with Greg Licholai and Derk Arts
High R&D costs aren’t due to a lack of innovation but inefficiencies in trials. Here’s how we can...
Clinical Trials Aren’t Just About Patients (and That’s Okay)
This article explores the debate between patient-centricity and protocol-centricity in clinical trials, featuring insights from Derk Arts (Castor)...
Strategies to Minimize Participant and Healthcare Provider Burden in Clinical Trials
This article examines strategies to reduce participant and provider burden in clinical trials while ensuring high-quality data collection....
What do we measure with PROs in head and neck cancer? Pain, QoL, adverse events and more
Patient-Reported Outcomes (PROs) are essential in head and neck cancer research, offering insights into symptoms, quality of life,...
A New Perspective on Clinical Research: Accessibility and Innovation
Joost Rigter’s inspiring journey highlights the importance of accessibility in clinical research. From AI-driven tools to simplified communication,...